MedTrace Logo

The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer

NCT01346371 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-03-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Refresh Tears 0.5% Lubricant Eye Drops

DRUG

Bepreve 1.5% Ophthalmic Solution

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • Minnesota Eye Consultants, P.A.

    lead INDUSTRY

Principal Investigators

  • Ahmad M Fahmy, O.D. · Minnesota Eye Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-08-31
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01346371 on ClinicalTrials.gov